Lexaria Bioscience Corp. (LEXX) vs PharmaCyte Biotech, Inc. (PMCB)
A side-by-side comparison of Lexaria Bioscience Corp. and PharmaCyte Biotech, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
LEXX
Lexaria Bioscience Corp.
$2.89HealthcareDelayed quote: Oct 6, 2026, 12:59 PM EDT
PMCB
PharmaCyte Biotech, Inc.
$0.43HealthcareDelayed quote: Oct 6, 2026, 12:59 PM EDT
Total return — LEXX vs PMCB
growth of $100 · dividends reinvested · last 6yLEXX -95.9% (-41.2%/yr)PMCB -98.6% (-50.9%/yr)LEXX compounded faster over this window
LEXX PMCB
LEXX vs PMCB: by the numbers
- •LEXX is the larger company ($5M vs $5M market cap).
- •Both run net losses; PMCB's is the smaller (0.00% vs -3985.58% net margin).
Metrics side by side
Valuation
| Metric | LEXX | PMCB |
|---|---|---|
| P/S ratio | 24.62 | N/A |
| P/B ratio | 1.01 | 0.16 |
Profitability
| Metric | LEXX | PMCB |
|---|---|---|
| Gross margin | 100.00% | 0.00% |
| Operating margin | -1683.01% | 0.00% |
| Net margin | -3985.58% | 0.00% |
| ROE | -163.18% | -54.15% |
| ROIC | -175.26% | -19.51% |
Growth (annualized)
| Metric | LEXX | PMCB |
|---|---|---|
| Revenue CAGR (5Y) | 12.92% | N/A |
| Total return CAGR (5Y) | -50.86% | -33.59% |
Frequently asked
- How have LEXX and PMCB total returns compared?
- Over the past 5 years, LEXX delivered -50.86% and PMCB delivered -33.59% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.